Inflammation may contribute to the pathogenesis of depression and antidepressants are hypothesised to have an anti-inflammatory effect. In this randomised double-blinded trial we investigated the cytokine levels in supernatants of stimulated whole blood samples from first degree relatives to patients with depression randomised to a single daily dose of either 10mg escitalopram or placebo for four weeks. No significant differences were found in any of the cytokine levels between the participants treated with escitalopram (n=21) or placebo (n=23). Our data does thus not support the hypothesis of a global anti-inflammatory effect of escitalopram on cytokines in healthy subjects.